<!DOCTYPE html><html><head><title> Pacifica Code Section 26-18-S103 </title><link rel="stylesheet" href="../../../assets/style.css"/></head><body>
<b><i>
                      Effective 5/12/2020</i></b>
<br>
<b>26-18-103.&nbsp;
          </b><b>DUR Board -- Responsibilities.</b>
<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The board shall:<a id="26-18-103(1)" name="26-18-103(1)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(1)</td><td style="width:99%">
develop rules necessary to carry out its responsibilities as defined in this part;</td>
</tr>
</tbody></table>
<a id="26-18-103(2)" name="26-18-103(2)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(2)</td><td style="width:99%">
oversee the implementation of a Medicaid retrospective and prospective DUR program in accordance with this part, including responsibility for approving provisions of contractual agreements between the Medicaid program and any other entity that will process and review Medicaid drug claims and profiles for the DUR program in accordance with this part;</td>
</tr>
</tbody></table>
<a id="26-18-103(3)" name="26-18-103(3)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(3)</td><td style="width:99%">
develop and apply predetermined criteria and standards to be used in retrospective and prospective DUR, ensuring that the criteria and standards are based on the compendia, and that they are developed with professional input, in a consensus fashion, with provisions for timely revision and assessment as necessary.  The DUR standards developed by the board shall reflect the local practices of physicians in order to monitor:
<a id="26-18-103(3)(a)" name="26-18-103(3)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
therapeutic appropriateness;</td>
</tr>
</tbody></table>
<a id="26-18-103(3)(b)" name="26-18-103(3)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
overutilization or underutilization;</td>
</tr>
</tbody></table>
<a id="26-18-103(3)(c)" name="26-18-103(3)(c)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(c)</td><td style="width:99%">
therapeutic duplication;</td>
</tr>
</tbody></table>
<a id="26-18-103(3)(d)" name="26-18-103(3)(d)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(d)</td><td style="width:99%">
drug-disease contraindications;</td>
</tr>
</tbody></table>
<a id="26-18-103(3)(e)" name="26-18-103(3)(e)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(e)</td><td style="width:99%">
drug-drug interactions;</td>
</tr>
</tbody></table>
<a id="26-18-103(3)(f)" name="26-18-103(3)(f)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(f)</td><td style="width:99%">
incorrect drug dosage or duration of drug treatment; and</td>
</tr>
</tbody></table>
<a id="26-18-103(3)(g)" name="26-18-103(3)(g)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(g)</td><td style="width:99%">
clinical abuse and misuse;</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-103(4)" name="26-18-103(4)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(4)</td><td style="width:99%">
develop, select, apply, and assess interventions and remedial strategies for physicians, pharmacists, and recipients that are educational and not punitive in nature, in order to improve the quality of care;</td>
</tr>
</tbody></table>
<a id="26-18-103(5)" name="26-18-103(5)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(5)</td><td style="width:99%">
disseminate information to physicians and pharmacists to ensure that they are aware of the board's duties and powers;</td>
</tr>
</tbody></table>
<a id="26-18-103(6)" name="26-18-103(6)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(6)</td><td style="width:99%">
provide written, oral, or electronic reminders of patient-specific or drug-specific information, designed to ensure recipient, physician, and pharmacist confidentiality, and suggest changes in prescribing or dispensing practices designed to improve the quality of care;</td>
</tr>
</tbody></table>
<a id="26-18-103(7)" name="26-18-103(7)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(7)</td><td style="width:99%">
utilize face-to-face discussions between experts in drug therapy and the prescriber or pharmacist who has been targeted for educational intervention;</td>
</tr>
</tbody></table>
<a id="26-18-103(8)" name="26-18-103(8)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(8)</td><td style="width:99%">
conduct intensified reviews or monitoring of selected prescribers or pharmacists;</td>
</tr>
</tbody></table>
<a id="26-18-103(9)" name="26-18-103(9)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(9)</td><td style="width:99%">
create an educational program using data provided through DUR to provide active and ongoing educational outreach programs to improve prescribing and dispensing practices, either directly or by contract with other governmental or private entities;</td>
</tr>
</tbody></table>
<a id="26-18-103(10)" name="26-18-103(10)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(10)</td><td style="width:99%">
provide a timely evaluation of intervention to determine if those interventions have improved the quality of care;</td>
</tr>
</tbody></table>
<a id="26-18-103(11)" name="26-18-103(11)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(11)</td><td style="width:99%">
publish the annual Drug Utilization Review report required under 42 C.F.R. Sec. 712;</td>
</tr>
</tbody></table>
<a id="26-18-103(12)" name="26-18-103(12)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(12)</td><td style="width:99%">
develop a working agreement with related boards or agencies, including the State Board of Pharmacy, Physicians' Licensing Board, and SURS staff within the division, in order to clarify areas of responsibility for each, where those areas may overlap;</td>
</tr>
</tbody></table>
<a id="26-18-103(13)" name="26-18-103(13)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(13)</td><td style="width:99%">
establish a grievance process for physicians and pharmacists under this part, in accordance with <a href="../../Title63G/Chapter4/63G-4.html?v=C63G-4_1800010118000101">Title 63G, Chapter 4, Administrative Procedures Act</a>;</td>
</tr>
</tbody></table>
<a id="26-18-103(14)" name="26-18-103(14)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(14)</td><td style="width:99%">
publish and disseminate educational information to physicians and pharmacists concerning the board and the DUR program, including information regarding:
<a id="26-18-103(14)(a)" name="26-18-103(14)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
identification and reduction of the frequency of patterns of fraud, abuse, gross overuse, inappropriate, or medically unnecessary care among physicians, pharmacists, and recipients;</td>
</tr>
</tbody></table>
<a id="26-18-103(14)(b)" name="26-18-103(14)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
potential or actual severe or adverse reactions to drugs;</td>
</tr>
</tbody></table>
<a id="26-18-103(14)(c)" name="26-18-103(14)(c)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(c)</td><td style="width:99%">
therapeutic appropriateness;</td>
</tr>
</tbody></table>
<a id="26-18-103(14)(d)" name="26-18-103(14)(d)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(d)</td><td style="width:99%">
overutilization or underutilization;</td>
</tr>
</tbody></table>
<a id="26-18-103(14)(e)" name="26-18-103(14)(e)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(e)</td><td style="width:99%">
appropriate use of generics;</td>
</tr>
</tbody></table>
<a id="26-18-103(14)(f)" name="26-18-103(14)(f)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(f)</td><td style="width:99%">
therapeutic duplication;</td>
</tr>
</tbody></table>
<a id="26-18-103(14)(g)" name="26-18-103(14)(g)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(g)</td><td style="width:99%">
drug-disease contraindications;</td>
</tr>
</tbody></table>
<a id="26-18-103(14)(h)" name="26-18-103(14)(h)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(h)</td><td style="width:99%">
drug-drug interactions;</td>
</tr>
</tbody></table>
<a id="26-18-103(14)(i)" name="26-18-103(14)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
incorrect drug dosage and duration of drug treatment;</td>
</tr>
</tbody></table>
<a id="26-18-103(14)(j)" name="26-18-103(14)(j)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(j)</td><td style="width:99%">
drug allergy interactions; and</td>
</tr>
</tbody></table>
<a id="26-18-103(14)(k)" name="26-18-103(14)(k)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(k)</td><td style="width:99%">
clinical abuse and misuse;</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-103(15)" name="26-18-103(15)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(15)</td><td style="width:99%">
develop and publish, with the input of the State Board of Pharmacy, guidelines and standards to be used by pharmacists in counseling Medicaid recipients in accordance with this part.  The guidelines shall ensure that the recipient may refuse counseling and that the refusal is to be documented by the pharmacist.  Items to be discussed as part of that counseling include:
<a id="26-18-103(15)(a)" name="26-18-103(15)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
the name and description of the medication;</td>
</tr>
</tbody></table>
<a id="26-18-103(15)(b)" name="26-18-103(15)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
administration, form, and duration of therapy;</td>
</tr>
</tbody></table>
<a id="26-18-103(15)(c)" name="26-18-103(15)(c)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(c)</td><td style="width:99%">
special directions and precautions for use;</td>
</tr>
</tbody></table>
<a id="26-18-103(15)(d)" name="26-18-103(15)(d)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(d)</td><td style="width:99%">
common severe side effects or interactions, and therapeutic interactions, and how to avoid those occurrences;</td>
</tr>
</tbody></table>
<a id="26-18-103(15)(e)" name="26-18-103(15)(e)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(e)</td><td style="width:99%">
techniques for self-monitoring drug therapy;</td>
</tr>
</tbody></table>
<a id="26-18-103(15)(f)" name="26-18-103(15)(f)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(f)</td><td style="width:99%">
proper storage;</td>
</tr>
</tbody></table>
<a id="26-18-103(15)(g)" name="26-18-103(15)(g)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(g)</td><td style="width:99%">
prescription refill information; and</td>
</tr>
</tbody></table>
<a id="26-18-103(15)(h)" name="26-18-103(15)(h)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(h)</td><td style="width:99%">
action to be taken in the event of a missed dose; and</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-103(16)" name="26-18-103(16)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(16)</td><td style="width:99%">
establish procedures in cooperation with the State Board of Pharmacy for pharmacists to record information to be collected under this part.  The recorded information shall include:
<a id="26-18-103(16)(a)" name="26-18-103(16)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
the name, address, age, and gender of the recipient;</td>
</tr>
</tbody></table>
<a id="26-18-103(16)(b)" name="26-18-103(16)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
individual history of the recipient where significant, including disease state, known allergies and drug reactions, and a comprehensive list of medications and relevant devices;</td>
</tr>
</tbody></table>
<a id="26-18-103(16)(c)" name="26-18-103(16)(c)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(c)</td><td style="width:99%">
the pharmacist's comments on the individual's drug therapy;</td>
</tr>
</tbody></table>
<a id="26-18-103(16)(d)" name="26-18-103(16)(d)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(d)</td><td style="width:99%">
name of prescriber; and</td>
</tr>
</tbody></table>
<a id="26-18-103(16)(e)" name="26-18-103(16)(e)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(e)</td><td style="width:99%">
name of drug, dose, duration of therapy, and directions for use.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<br>
<br>Amended by Chapter <a href="http://le.utah.gov/UtahCode/ChapterLookup.jsp?chap=225&amp;sess=2020GS">225</a>, 2020 General Session<br>
</body></html>